Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Buy” by Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been given a consensus recommendation of “Buy” by the five analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.38.

A number of equities analysts have recently weighed in on CRVS shares. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. Finally, Oppenheimer upped their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock opened at $4.41 on Friday. The stock has a market capitalization of $283.39 million, a price-to-earnings ratio of -4.74 and a beta of 1.07. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00. The stock’s 50 day moving average price is $5.28 and its two-hundred day moving average price is $6.01.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CRVS. RTW Investments LP purchased a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $14,335,000. Foresite Capital Management VI LLC purchased a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $8,460,000. Deerfield Management Company L.P. Series C purchased a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $5,350,000. Vivo Capital LLC raised its position in Corvus Pharmaceuticals by 49.2% in the 4th quarter. Vivo Capital LLC now owns 2,234,566 shares of the company’s stock valued at $11,955,000 after buying an additional 737,298 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in Corvus Pharmaceuticals in the 4th quarter valued at $2,678,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.